T
Topica Pharmaceuticals
Topical antifungal treatment for fungal nail infections
About Topica Pharmaceuticals
Topica Pharmaceuticals, Inc. was a privately held, clinical-stage specialty pharmaceutical company founded in 2008 and based in Palo Alto, California. The company's primary focus was the development and commercialization of luliconazole, a topical antifungal agent, for the treatment of onychomycosis, which are fungal infections of the nail. The company's business model centered on in-licensing promising drug candidates and advancing them through clinical development in the Americas and Europe.
Topica in-licensed its lead product, luliconazole, from Nihon Nohyaku Co., Ltd. This antifungal agent was already approved and marketed in Japan for treating tinea infections. The company's strategy was to develop a 10% luliconazole solution specifically for onychomycosis, a condition affecting over 35 million Americans with limited effective and safe topical treatments. Luliconazole showed high potency and the ability to rapidly penetrate the nail plate to reach the infection in the nail bed. The company was led by President and CEO Greg Vontz.
The company successfully completed a Phase 1/2a clinical trial in 2011, which demonstrated the safety and tolerability of its luliconazole solution. Following these positive results, Topica Pharmaceuticals secured $27 million in a Series B financing round in October 2011, led by Third Rock Ventures, with participation from existing investors Prospect Venture Partners and Yasuda Enterprise Development Corporation. This funding was intended to support a large-scale Phase 2b/3 clinical trial starting in 2012, with the goal of gaining FDA approval. The company raised a total of at least $28.7 million across its funding rounds. According to PitchBook, the company went out of business in May 2016.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jun 2013 | $32M | $126M | Undisclosed | — |
| SERIES BOther financing | Oct 2011 | $27M | $108M | Prospect Venture Partners · Yasuda Enterprise Development · Third Rock Ventures | — |
Growth signals
Latest recorded traffic for Topica Pharmaceuticals is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Topica Pharmaceuticals in the Los Altos ecosystem
The Topica Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Third Rock Ventures- PPProspect Venture Partners
- YDYasuda Enterprise Development
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Topica Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Topica Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








